Inhibitors of glutaminase or transaminase have shown the therapeutic efficacy in multiple MYC-driven tumour models, and a representative glutaminase inhibitor, CB-839, is currently under clinical trials for patient treatment. The gene discussed is GLS; the disease is neoplasm.